Catalyst Biosciences Inc (NASDAQ:CBIO) has been assigned an average broker rating score of 1.00 (Strong Buy) from the three analysts that cover the stock, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy recommendation.
Brokers have set a 1-year consensus price objective of $57.00 for the company and are expecting that the company will post ($1.41) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Catalyst Biosciences an industry rank of 195 out of 265 based on the ratings given to related companies.
A number of equities analysts recently weighed in on CBIO shares. ValuEngine upgraded shares of Catalyst Biosciences from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. Zacks Investment Research upgraded shares of Catalyst Biosciences from a “hold” rating to a “buy” rating and set a $5.25 price objective for the company in a research report on Wednesday, November 8th. B. Riley set a $19.00 price objective on shares of Catalyst Biosciences and gave the company a “buy” rating in a research report on Monday, December 18th. Finally, Chardan Capital increased their price objective on shares of Catalyst Biosciences from $10.00 to $75.00 and gave the company a “buy” rating in a research report on Friday, February 9th.
Shares of Catalyst Biosciences (CBIO) traded down $0.54 during trading hours on Wednesday, hitting $33.82. 545,151 shares of the company were exchanged, compared to its average volume of 528,192. Catalyst Biosciences has a 12-month low of $3.11 and a 12-month high of $37.00. The company has a market capitalization of $244.15, a price-to-earnings ratio of -2.58 and a beta of 2.68.
About Catalyst Biosciences
Catalyst Biosciences, Inc, formerly Targacept, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.